Allena Pharmaceuticals, Inc. P/S ratio

P/S ratio of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/S ratio growth rates and interactive chart. A valuation metric that measures the share price of a stock compared to its sales per share. It is used by investors mainly because it’s less volatile than P/E and less subject to accounting manipulation. A low P/S ratio compare to historical average or other companies in the same industry might indicate undervaluation.


Highlights and Quick Summary

Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/S ratio of Allena Pharmaceuticals, Inc.

Most recent P/S ratioof ALNA including historical data for past 10 years.

Interactive Chart of P/S ratio of Allena Pharmaceuticals, Inc.


Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.